Actinium Pharmaceuticals, Inc. (ATNM) is a Biotechnology company in the Healthcare sector, currently trading at $1.10. It has a SharesGrow Score of 54/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Analyst consensus target is ATNM = $11 (+906.4% upside).
Valuation: ATNM trades at a trailing Price-to-Earnings (P/E) of -1 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.3.
Financials: revenue is $90,000, -96.1%/yr average growth. Net income is $34M (loss), growing at -4.9%/yr. Net profit margin is -37652.2% (negative). Gross margin is 100% (+67.9 pp trend).
Balance sheet: total debt is $2M against $8M equity (Debt-to-Equity (D/E) ratio 0.22, conservative). Current ratio is 6.2 (strong liquidity). Debt-to-assets is 3.3%. Total assets: $52M.
Analyst outlook: 11 / 11 analysts rate ATNM as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 50/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).
